Different Effects of Angiotsensin II and Angiotensin-(1-7) on Vascular Smooth Muscle Cell Proliferation and Migration

Feng Zhang1,2, Yanhua Hu3, Qingbo Xu3, Shu Ye1

1 William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 2 Department of Physiology and Pathophysiology, Health Science Center, Peking University, Beijing, China, 3 Cardiovascular Division, King’s BHF Centre, King’s College London, London, United Kingdom

Abstract

**Background:** Angiotsensin (Ang) II and Ang-(1-7) are two of the bioactive peptides of the rennin-angiotensin system. Ang II is involved in the development of cardiovascular disease, such as hypertension and atherosclerosis, while Ang-(1-7) shows cardiovascular protection in contrast to Ang II.

**Methodology/Principal Findings:** In this study, we investigated effects of Ang II and Ang-(1-7) on vascular smooth muscle cell (SMC) proliferation and migration, which are critical in the formation of atherosclerotic lesions. Treatment with Ang II resulted in an increase of SMC proliferation, whereas Ang-(1-7) alone had no effects. However, preincubation with Ang-(1-7) inhibited Ang II-induced SMC proliferation. Ang II promoted SMC migration, and this effect was abolished by pretreatment with Ang-(1-7). The stimulatory effects of Ang II on SMC proliferation and migration were blocked by the Ang II receptor antagonist losartan, while the inhibitory effects of Ang-(1-7) were abolished by the Ang-(1-7) receptor antagonist A-799. Ang II treatment caused activation of ERK1/2 mediated signaling, and this was inhibited by preincubation of SMCs with Ang-(1-7).

**Conclusion:** These results suggest that Ang-(1-7) inhibits Ang II-induced SMC proliferation and migration, at least in part, through negative modulation of Ang II induced ERK1/2 activity.

Introduction

Vascular smooth muscle cell migration and proliferation are important processes in the development of restenosis after angioplasty and in the formation of atherosclerotic plaques [1,2]. After angioplasty, SMCs migrate from media into intima, where they contribute to neointima formation and restenosis. This process is also an important feature in the development of neovascular atherosclerotic lesions, in which fibrous cap is characterized by the accumulation of SMCs and SMC-derived extracellular matrix.

Angiotsensin II, one of the major active components in the rennin-angiotensin system, plays an essential role in the pathogenesis of atherosclerosis [3]. Most of the pathophysiological actions of Ang II are mediated by signal transduction through the AT1 receptor. The AT1 receptor, which contains 7 transmembrane helices, is a member of superfamily of G protein-coupled receptors. This receptor mediates the effects of Ang II on vasoconstriction, proliferation, inflammation, coagulation and extracellular matrix remodeling.[4] During the development of atherosclerosis, Ang II, acting through AT1 receptor, induces vascular SMC growth and migration [1,4].

An major Ang II-induced signaling pathway is activation of mitogen-activated protein kinases, including extracellular signal-regulated kinase (ERK1/2) [5], p38 mitogen-activated protein kinase (p38 MAPK) [6], and c-Jun N-terminal kinase (c-JNK) [7]. ERK1/2 has been reported to be a critical regulatory factor for Ang II-mediated growth and migration of vascular SMCs [5,8–11]. Inhibition of ERK1/2 decreases Ang II-induced vascular SMC proliferation and migration [5,11].

Angiotsensin-(1-7), another bioactive peptide of the rennin-angiotensin system, appears to exert cardiovascular protection in contrast to Ang II. Ang-(1-7), which can be converted from Ang II by ACE2, has vasodilator and anti-proliferative properties [12]. In addition, it has been shown that Ang-(1-7) attenuates ventricular hypertrophy and fibrosis in response to the hypertensive challenge by Ang II [13]. The effects of Ang-(1-7) are mediated via the MAS receptor, another G-protein-coupled, seven transmembrane protein [14]. The peptide has been shown to oppose many actions of Ang II [15], and to counterregulate Ang II-induced ERK1/2 activity [16–18].
There are studies showing the effect of Ang-(1-7) on vascular SMC proliferation [16,19]. Nevertheless, the effect of Ang-(1-7) on vascular SMC migration has not been well investigated. There is evidence showing that intravenous infusions of Ang-(1-7) attenuates neointimal formation after vascular injury and stent implantation in rats [20,21], which could be in part due to effects of Ang-(1-7) on SMC migration into the neointima. In this study, we investigated possible effects of Ang-(1-7) on vascular SMC proliferation and migration. We found that Ang-(1-7) inhibited Ang II-induced vascular SMC proliferation and migration, and this inhibitory effect was via the MAS receptor. Furthermore, we found that Ang-(1-7) treatment suppressed Ang II-induced activation of ERK1/2 mediated signaling, a possible mechanism for its inhibitory effect on SMC proliferation and migration.

Results

Ang-(1-7) inhibits Ang II-induced SMC proliferation

RT-PCR and subsequent sequence analysis showed that the SMCs expressed both the Ang II AT1 receptor and the Ang-(1-7) MAS receptor. To study effects of Ang II and Ang-(1-7) on SMC proliferation, same numbers of cells were seeded in individual wells of 6-well plates, cultured in the presence or absence of Ang II or Ang-(1-7) or both (Ang-(1-7) was added 10 min before the addition of Ang II) at a final concentration of 10^{-7} M for four days, and then the total numbers of cells per well were determined using a cell counter. As shown in Figure 1, there was a significantly greater increase in cell number when treated with Ang II, as compared with the untreated control. In contrast, treatment with Ang-(1-7) alone did not alter the rate of cell proliferation. However, when the cells were preincubated with Ang-(1-7), Ang II-induced SMC proliferation was significantly inhibited (Figure 1).

MAS receptor antagonist abrogates the effects of Ang-(1-7) on SMC proliferation

As Ang II mediates most of its effects via the AT1 receptor and Ang-(1-7) mediates its effects via the MAS receptor, we then used the AT1 receptor antagonist losartan and the MAS receptor antagonist A-779 to investigate whether Ang II and Ang-(1-7) exerted their effects on SMC proliferation via these two receptors respectively. As shown in Figure 2, the AT1 receptor antagonist losartan blocked Ang II-induced SMC proliferation, whilst the MAS receptor antagonist A-779 abrogated the anti-proliferative effect of Ang-(1-7) on Ang II-induced SMC proliferation.

Ang-(1-7) modulates Ang II-stimulated SMC migration

To study effects of Ang II and Ang-(1-7) on SMC migration, SMCs were subjected to migration assays, in the presence or absence of Ang II or Ang-(1-7) or both (Ang-(1-7) was added 10 min before the addition of Ang II). The experiments showed that Ang II increased SMC migration, whereas Ang-(1-7) alone had no effect (Figure 3). However, cells treated with both Ang II and Ang-(1-7) had significant lower rate of migration compared with cells treated with Ang II alone (Figure 3), suggesting that Ang-(1-7) inhibited the stimulating effect of Ang II on SMC migration.
MAS receptor antagonist blocks the effect of Ang-(1-7) on SMC migration

To investigate whether the stimulating effect of SMC migration was mediated via the AT1 receptor and whether the counteracting effect of Ang-(1-7) was mediated by the MAS receptor, we performed the migration assays in the presence or absence of the AT1 receptor antagonist losartan or the MAS receptor antagonist A-779. As shown in Figure 4, Ang II-induced SMC migration was inhibited by AT1R antagonist losartan, while the inhibitory effect of Ang-(1-7) on Ang II-induced SMC migration was blocked by A-779.

Ang-(1-7) inhibits AngII-induced ERK1/2 phosphorylation

Since the ERK1/2 signaling pathway plays a major role in Ang II-induced SMC proliferation and migration [5,11], we investigated whether Ang-(1-7) interfered with Ang II-induced ERK1/2 activation. We found that Ang II treatment stimulated phosphorylation of ERK1/2 and that this effect was significantly inhibited in the presence of Ang-(1-7) (Figure 5).

Discussion

Our study show that Ang-(1-7) and Ang II exert different effects on vascular SMC proliferation and migration. Our study confirms the reported stimulating effects of Ang II on SMC proliferation and migration, supporting the notion that increased Ang II generation can promote atherogenesis and neointimal formation leading to restenosis after angioplasty [22]. Similar to previous studies which showed that Ang-(1-7) inhibits proliferation in a number of cell types [19,23-25], we observed that Ang-(1-7) negatively modulates Ang II-induced vascular SMC proliferation. Besides, the most important finding of our study is that Ang-(1-7) inhibits Ang II-induced SMC migration. This novel finding provides a further rationale for the use of Ang-(1-7) as a therapeutic agent for preventing neointimal formation and restenosis after angioplasty [26,27]. We found that the inhibitory effect of Ang-(1-7) on Ang II-stimulated SMC proliferation and migration can be blocked by the MAS receptor antagonist A-779, indicating that Ang-(1-7) exerts this effect via activating the MAS receptor. Furthermore, we show that Ang-(1-7) inhibits Ang II-induced ERK1/2 phosphorylation, which provides a plausible explanation for the molecular mechanism underlying the inhibitory effect of Ang-(1-7) on Ang II-stimulated SMC proliferation and migration, since the ERK1/2 dependent signaling pathway plays a critical role in mediating the stimulating effect of Ang II on SMC proliferation and migration.

In our study, we observed that Ang-(1-7) inhibits Ang II-induced vascular SMC proliferation. Interestingly, whilst Ang II has been shown to induce proliferation of many cell types including vascular SMCs, [22] divergent effects have been reported for Ang-(1-7) in different cell types. It has been shown that Ang-(1-7) causes inhibition of proliferation of rat vascular SMCs, myocytes and human lung cancer cells, [19,23,24] and that Ang-(1-7) treatment attenuates neointimal formation after stent implantation in rats [20]. On the other hand, Ang-(1-7) stimulates proliferation of endothelia progenitor cells and hematopoietic progenitor cells [28,29]. Moreover, similar to our finding in mouse SMCs, Ang-(1-7) alone has no effect on mesangial cell growth, whereas Ang-(1-7) inhibits Ang II-induced increase in mesangial cell proliferation [25]. The reasons for these divergent effects of Ang-(1-7) are currently unknown and might be due to differences in the repertoires of receptors, signaling molecules and cell cycling regulators, etc, in the different types of cells. There is a reported study showing direct inhibition of rat vascular SMC proliferation by Ang-(1-7) [19], which differ from our finding in mouse SMCs, possibly because of the different animal specials and experiment conditions.

It has been well established that Ang II is a potent stimulus for vascular SMC migration [5,6,8,10,30]. In contrast, it was unclear whether Ang-(1-7) also had a effect on SMC migration, although there are several studies from which there is indirect evidence to suggest that this might be the case. Some of these studies showed that Ang-(1-7) treatment attenuated neointimal formation after vascular injury and stent implantation in the rat [20,27]. Similarly, another study showed that Ang-(1-7) treatment resulted in a reduction of neointimal formation and collagen synthesis after angioplasty in rabbits [26]. As SMC migration is a critical step in the formation of neointima, it is possible that the reduction in neointimal formation as a result of Ang-(1-7) in these studies might be in part due to an inhibitory effect of Ang-(1-7) on SMC migration. The finding of our study that Ang-(1-7) inhibits Ang II-induced SMC migration provides direct evidence that supports this notion.

Our study shows that Ang II-induced ERK1/2 activation is negatively modulated by Ang-(1-7). Previous studies have shown that activation of ERK1/2 plays an important role in SMC migration. ERK1 and ERK2 are rapidly activated in rat carotid arteries after balloon injury [31]. Downregulation of ERK1/2 by antisense oligonucleotides or gene transfer of a dominant-negative mutant of ERK1/2 prevents neointimal formation in balloon angioplasty [32]. In addition, it has been shown that the effect of Ang II on vascular SMC migration are mediated via an AT1 receptor dependent signaling pathway involving activation of ERK1/2 [9], and that blocking ERK1/2 activation using the MAPK kinase inhibitor PD98059 or antisense oligodeoxynucleotides can significantly attenuate Ang II-stimulated SMC migration [5]. In the present study, we found that Ang-(1-7) reduced Ang II-stimulated ERK1/2 activity. It is likely that Ang-(1-7) can activate a signaling pathway that leads to blockage of ERK1/2 activation and therefore can inhibit Ang II-induced ERK activation and Ang II-stimulated SMC migration.

Figure 4. Blockade of the effects of Ang II and Ang-(1-7) on SMC migration by antagonists. Data shown are mean ± SEM of migration distance from 4 experiments, each with triplicate wells per condition.
doi:10.1371/journal.pone.0012323.g004
There are several possibilities for the mechanism by which Ang-(1-7) regulates SMC migration. Firstly, inhibition of the ERK1/2-dependant signal cascade by Ang-(1-7) is likely to play a role in reduced cell migration. Substrates of ERK1/2 include FAK (focal adhesion kinase) and paxillin [33,34]. ERK1/2-dependant FAK and paxillin phosphorylation is important in the regulation of focal contacts during cell migration [35]. Ang II-induced activation of c-Src, another vital component in the regulation of focal contacts formation, has been shown to be abrogated by Ang-(1-7) in human endothelial cells, and c-Src is upstream of the ERK signaling cascade [18]. Ang-(1-7) antagonizes Ang II-mediated upregulation of matrix metalloproteinase (MMP)-9 [36], an extracellular matrix protein-degrading enzyme known to play an important role in cell migration [37]. MMP-9 expression has been shown to be mediated by ERK1/2, and inhibition of ERK1/2 downregulates MMP-9 expression in vascular SMCs and in arterialized vein grafts [38,39]. As our study showed that Ang-(1-7) abrogated Ang II-mediated ERK1/2 activation, it is likely that Ang-(1-7) can counteract Ang II-induced SMC migration through inhibiting FAK and paxillin phosphorylation and MMP-9 expression via the ERK1/2 pathway. Secondly, Ang-(1-7) is a bioactive peptide that stimulates nitric oxide release [40,41], and nitric oxide is known to inhibit Ang II-induced SMC migration [40,42]. Thirdly, Ang-(1-7) can downregulate AT1 receptor, resulting in reduced Ang II binding in vascular SMCs [43]. The first evidence for an interaction between Ang-(1-7) and Ang II is the inhibition of the contractile effect of Ang II in the rabbit aorta by the Ang-(1-7) analogue Sar-Ang-(1-7) [44]. Further studies show that Ang-(1-7) antagonizes Ang II-induced contraction of human vessels, including internal mammary arteries and forearm resistant vessels [28,45,46]. Ang-(1-7) blockade of Ang II-induced contraction results from release of vasorelaxing factors including NO and prostaglandins [40], or other biologically active peptides such as bradykinin [47]. In addition, it has been shown that Ang-(1-7) prevents Ang II-induced cardiac remodeling, attenuating myocyte hypertrophy and myocardial interstitial fibrosis induced by Ang II [48]. The finding of our study that Ang-(1-7) inhibits the effect of Ang II on SMC proliferation and migration suggests that the interaction between Ang-(1-7) and Ang II could also occur in vascular remodeling via affecting SMC proliferation and migration.

The findings from the previous and present studies of different effects of Ang II and Ang-(1-7), which represent two major members of the rennin-angiotensin system, are directly relevant to understanding the

![Figure 5. Ang-(1-7) inhibits Ang II-induced ERK1/2 phosphorylation. (A) Representative Western blotting results, showing bands for phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2. (B) Quantification of band intensity of Western blots. Data shown are mean ± SEM of 3 experiments. doi:10.1371/journal.pone.0012323.g005](https://www.plosone.org/figure?cid=1234567890)
Materials and Methods

Materials

Ang II, Ang-(1-7), losartan, Dulbecco's modified Eagle's medium (DMEM), penicillin and streptomycin were obtained from Sigma Aldrich. A-779 was purchased from Phoenix Pharmaceuticals. Fetal bovine serum (FBS) was obtained from Invitrogen. Antibodies to phospho-ERK1/2 and to total ERK1/2 were from Cell signaling.

Cell culture

SMCs were isolated by autogrowth of explant culture from the thoracic aortas of mice as described before [49], which was approved by King's College Ethical Review Process Committee and under the UK Home Office Animal Scientific Procedures Division permit number 70/6458. Briefly, mouse thoracic aorticas were removed and washed with DMEM. Intima and inner two thirds of media were carefully dissected from the vessels, cut into pieces (≈1 mm³). Tissue pieces were then explanted onto a 0.02% gelatin-coated flask. To get a firm attachment of tissue pieces, the flask was incubated upside-down for 1 h and then DMEM supplemented with 20% FBS, penicillin and streptomycin was slowly added. Cells were allowed to autogrow for 2 weeks and then passaged until enough cells were obtained. Cells were then maintained in DMEM supplemented with 10% FBS, penicillin and streptomycin at 37 °C in a humidified atmosphere of 5% CO₂.

Reverse-transcriptase polymerase chain reaction (RT-PCR)

RNA was isolated from cultured SMCs using Nucleospin RNA II 50 Prep (Fisher Scientific) according to the manufacturer’s instruction. Single-stranded cDNA was synthesized from 1 μg of total RNA using 0.5 μg random primers and 200 units of M-MLV reverse transcriptase (Promega). PCR of the AT1 receptor and the MAS receptor were carried out. The sequences of PCR primers for AT1-R were 5'-GGACATCATCTTTGTTGGTG3' (sense) and 5'-ATCAGCACATCCAGGAATG-3' (anti-sense), which produced a 395 bp product. The PCR primer sequences for the MAS receptor were 5'-GGACATCATCTTTGTTGGTG3' (sense) and 5'-ATCAGCACATCCAGGAATG-3' (anti-sense) as described elsewhere [50], which generated a 690 bp PCR product. The PCR primer sequences for the MAS receptor were 5'-GGACATCATCTTTGTTGGTG3' (sense) and 5'-ATCAGCACATCCAGGAATG-3' (anti-sense) as described previously [50], which generated a 690 bp PCR product. The PCR primer sequences for the MAS receptor were 5'-GGACATCATCTTTGTTGGTG3' (sense) and 5'-ATCAGCACATCCAGGAATG-3' (anti-sense) as described elsewhere [50], which generated a 690 bp PCR product. The PCR primer sequences for the MAS receptor were 5'-GGACATCATCTTTGTTGGTG3' (sense) and 5'-ATCAGCACATCCAGGAATG-3' (anti-sense) as described elsewhere [50], which generated a 690 bp PCR product.

Measurement of cell proliferation

Some numbers of SMCs were seeded in different wells on 6-well tissue culture plates, cultured in the presence of 1% FBS and stimulated with Ang-(1-7) (10⁻⁷ M) or Ang II (10⁻⁷ M) or both (Ang-(1-7) was added 10 minutes before the addition of Ang II). In some conditions, cells were preincubated with losartan (10⁻⁶ M) or A-799 (10⁻⁶ M) or Ang II (10⁻⁷ M) for 5 minutes followed by treatment with Ang II or Ang-(1-7). The medium was changed and the cells were restimulated every 24 hours. After four days, cells were removed from each well using trypsin/EDTA and cell numbers were counted by a Vi-CELL cell viability analyzer (Beckman Coulter).

Migration assay

SMC migration was measured using a previously described method [51,52]. Briefly, cells were grown to confluence on 6-well plates. Parallel lines were drawn with a marker pen on the back of each well. Liner wounds were made vertical to these parallel lines by scraping each well with a sterile 200-μl pipette tip. Cells were then rinsed twice with serum-free medium to remove cellular debris. Images besides each crossing of parallel lines and wounds were obtained using an Olympus inverted microscope equipped with a camera. Cells were incubated with or without losartan (10⁻⁶ M) or A-799 (10⁻⁶ M) for 5 minutes, then with or without the addition of Ang II (10⁻⁷ M) or Ang-(1-7) (10⁻⁷ M), or with the addition of Ang-(1-7) 10 minutes before addition of Ang II (10⁻⁷ M). After 24 hours, images were taken again besides each crossing. ImageJ software was used to measure the distance between two edges of each wound. Data are presented as moving distance, which is the difference in the distances between two edges at the same crossing at 0 h and 24 h.

Western blotting

SMCs in serum-free media were incubated with or without Ang-(1-7) (10⁻⁷ M) for 5 minutes. Ang II (10⁻⁷ M) was then added and incubation was continued for an additional 30 minutes. Cell lysates were prepared in lysis buffer (1% SDS, 62.5 mM Tris-HCl, pH 7.8) containing protease inhibitor cocktail and phosphatase inhibitor cocktail (Sigma Aldrich) and protein concentrations were measured by a Bradford assay. Solubilized proteins (20 μg/well) were separated in 10% SDS-polyacrylamide gel by electrophoresis and transferred to nitrocellulose membranes. In the presence of 5% nonfat milk in Tris-buffered saline Tween 20 to block nonspecific binding, the membranes were hybridized overnight with an antibody for phosphorylated ERK1/2 (anti-phospho-ERK1/2, 1:2000) or an antibody for total ERK1/2 (anti-total ERK1/2, 1:1000), followed by incubation with a second antibody coupled to horseradish peroxidase. Immunoreactive bands were detected using a chemiluminescence (ECL) system and X-ray films. Densitometric analysis of bands was performed using Adobe Photoshop software.

Statistical analyses

All results are expressed as mean ± SEM. The data were evaluated by paired t-test and confirmed by Wilcoxon test. A value of P<0.05 was considered significant.

Author Contributions

Conceived and designed the experiments: FZ QX SY. Performed the experiments: FZ YH. Analyzed the data: FZ. Contributed reagents/materials/analysis tools: QX SY. Wrote the paper: FZ QX SY.

References

1. Lusis AJ (2000) Atherosclerosis. Nature 407: 233–241.
2. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, et al. (1991) Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253: 1129–1132.
3. Weiss D, Sorensen B, Taylor WR (2001) Angiotensin II and atherosclerosis. An J Cardiol 87: 23C–32C.
4. Tovy R, Schiffrin EL (2000) Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52: 639–672.
5. Xi XP, Graf K, Goetze S, Fleck E, Hsueh WA, et al. (1999) Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19: 73–82.
6. Lee HM, Lee CK, Lee SH, Roh HY, Bae YM, et al. (2007) p38 mitogen-activated protein kinase contributes to angiotensin II-stimulated migration of rat aortic smooth muscle cells. J Pharmacol Sci 103: 74–81.
7. Ohtsu H, Mizuno M, Frank GD, Sato S, Inagami T, et al. (2005) Signal-crosstalk between Rhodocioid and eNOS/NOS2 terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc Biol 25: 1831–1836.
8. Yang X, Zhu MJ, Sreejayan N, Ren J, Du M (2005) Angiotensin II promotes smooth muscle cell proliferation and migration through release of heparin-binding epidermal growth factor and activation of EGF receptor pathway. Mol Cells 20: 263–270.
9. Kyaw M, Yoshibumi M, Toshihika K, Kagami S, Izawa Y, et al. (2004) Src and Cas are essentially but differentially involved in angiotensin II-stimulated migration of vascular smooth muscle cells via extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase activation. Mol Pharmacol 65: 872–841.
10. Magabe BE, Yaghini FA, Song CY, Buharaliah CK, Waters CM, et al. (2009) Angiotensin II-induced migration of vascular smooth muscle cells is mediated by p38 mitogen-activated protein kinase-activated Src through spleen tyrosine kinase and p38 mitogen-activated protein kinase receptor transactivation. J Pharmacol Exp Ther 332: 116–124.
11. Touny RM, Deng LY, He G, Wu XH, Schifflin IR. (1999) Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases. J Hypertens 17: 907–916.
12. Keidar S, Kaplan M, Gamal-Lazaroевич A (2007) ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res 73: 463–469.
13. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, et al. (2008) Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103: 1319–1326.
14. Santos RA, Simoes e Silva AG, Marie C, Silva DM, Machado RP, et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8250–8256.
15. Souza Dos Santos RA, Passaço KT, Pesquero JB, Bader M, Simoes ESAC (2001) Interactions between angiotensin-(1-7), kinins, and angiotensin II in kidney and blood vessels. Hypertension 30: 660–664.
16. Tallant EA, Clark MA (2003) Molecular mechanisms of inhibition of vascular growth by angiotensin(1-7). Hypertension 42: 574–579.
17. Su Z, Zempelmann J, Burns KD (2006) Angiotensin(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 69: 2212–2218.
18. Sampaio WO, Henrique de Castro C, Santos RA, Schiffrin EL, Touyz RM (2006) Angiotensin(1-7) inhibits vascular smooth muscle cell growth. Hypertension 28: 104–108.
19. Keitsch H, Brodowscky S, Malinski T, Wiemer G (2001) Angiotensin-(1-7)- Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells. Hypertension 37: 72–76.
20. Dubey RK, Jackson EK, Luscher TF (1995) Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin I receptor. J Clin Invest 96: 141–149.
21. Freeman EJ, Chaisom GM, Ferrario CM, Tallant EA (1996) Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 28: 104–108.
22. Langelveld B, van Gilst WH, Tio RA, Bader M, Waters CM, et al. (2009) Angiotensin(1-7)- attenuates neointimal formation after stent implantation in the rat. Arterioscler Thromb Vasc Biol 29: 2527–2532.
23. Sharony R, Pinucci G, Saunders PC, Grossi EA, Baumann FG, et al. (2006) Matrix metalloproteinase expression in vein grafts: role of inflammatory mediators and extracellular signal-regulated kinases-1 and -2. Am J Physiol Heart Circ Physiol 290: H1651–1659.
24. Mugabe BE, Yaghini FA, Song CY, Buharaliah CK, Waters CM, et al. (2009) Angiotensin II-induced migration of vascular smooth muscle cells is mediated by p38 mitogen-activated protein kinase-activated Src through spleen tyrosine kinase and p38 mitogen-activated protein kinase receptor transactivation. J Pharmacol Exp Ther 332: 116–124.
25. Zhang J, Noble NA, Border WA, and Huang Y. Infusion of angiotensin-(1-7) inhibits vascular smooth muscle cell migration after angioplasty through the regulation of the TGF-beta/Smad signaling pathway in rabbits. Biochem Biophys Res Commun 350: 138–144.
26. Stravan WB, Ferrario CM, Tallant EA (1999) Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 33: 207–211.
27. Wang Y, Qian C, Roks A, Westerman D, Schumacher SM, et al. Circulating Rather than Cardiac Angiotensin-(1-7) Stimulates Cardioprotection Post Myocardial Infarction. Circ Heart Fail;.
28. Heringer-Wahler S, Eckert K, Schumacher SM, Uharek L, Wulf-Goldenberg A, et al. (2009) Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica 94: 857–860.
29. Yoshida O, Hirayama H, Nanasato M, Wataanabe T, Murakami T (2003) The angiotensin II receptor blocker candesartan cilexetil reduces angiogenesis after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. Am Heart J 149: e2.
30. Hu Y, Cheng L, Hochheimer BW, Xu Q (1997) Activation of mitogen-activated protein kinases (ERK/JNK) and AP-1 transcription factor in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol 17: 2800–2816.
31. IzuMI Y, Kim S, Namba M, Yasumoto H, Miyazaki H, et al. (2001) Gene transfer of dominant-negative mutants of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in balloon-injured rat artery. Circ Res 85: 1120–1126.
32. Hunger-Glaser I, Salazar EP, Sigmund SM, Krozengurt E (2003) Bombesin, lysosphosphatidic acid, and epidermal growth factor rapidly stimulate focal adhesion kinase phosphorylation at Src-910: requirement for ERK activation. J Biol Chem 278: 22631–22634.
33. Liu ZX, Yu CF, Nickel C, Thomas S, Canley LG (2002) Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin focal adhesion kinase association. J Biol Chem 277: 10452–10458.
34. Mitra SK, Hanson DA, Schlaper PD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6: 56–68.
35. Pan CIH, Wen CH, Liu CS (2008) Interplay of angiotensin II and angiotensin-(1-7) in the regulation of matrix metalloproteinases of human cardiocytes. Exp Physiol 93: 599–612.
36. Galin ZS, Johnson C, Godin D, Magid R, Shipley JM, et al. (2002) Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 91: 852–859.
37. Cho A, Graves J, Reidy MA (2000) Nitrogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 20: 2527–2532.
38. Lee HM, Lee CK, Lee SH, Roh HY, Bae YM, et al. (2007) p38 mitogen-activated protein kinase participates to angiotensin II-stimulated migration of rat aortic smooth muscle cells. J Pharmacol Sci 103: 74–81.